Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Discovery
Sponsor : BridgeBio Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Invitae Partners with BridgeBio to Leverage Genetic Insights for Rare Disease Therapies
Details : The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery of novel therapeutic targets for rare diseases and other unmet medical needs.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 30, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Discovery
Sponsor : BridgeBio Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : PRAX-222
Therapeutic Area : Neurology
Study Phase : IND Enabling
Recipient : Praxis Bioresearch
Deal Size : Inapplicable
Deal Type : Inapplicable
Invitae’s Real-World Ciitizen Data Utilized in Praxis Precision Medicines’ PRAX-222 IND Filing
Details : PRAX-222 is an ASO designed to selectively decrease SCN2A gene expression, directly targeting the underlying cause of early-seizure-onset SCN2A-DEE to treat seizures and other symptoms in patients with gain-of-function SCN2A mutations.
Product Name : PRAX-222
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
September 20, 2022
Lead Product(s) : PRAX-222
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Recipient : Praxis Bioresearch
Deal Size : Inapplicable
Deal Type : Inapplicable